Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Chambery – page 13

785 clinical trials in Chambery, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Chambery at a glance
785
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

785 trials in Chambery

Open in trial search

Urticaria chronic

Recruiting

Evaluation of remibrutinib (LOU064) effectiveness and safety in adult patients with chronic urticaria: A 12-week placebo-controlled study

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

Plasma cell myeloma

Recruiting

Study of elranatamab and lenalidomide combination versus standard chemotherapy and transplant in newly diagnosed multiple myeloma patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Intergroupe Francophone Du Myelome

Narcolepsy+1

Recruiting

Long-Term Study on the Safety and Effects of ALKS 2680 for Patients with Narcolepsy Type 1 and Type 2

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ALKS 2680
  • Sponsor:Alkermes Inc.

Acute myeloid leukaemia

Recruiting

Study of L-Annamycin and Cytarabine for Adults with Refractory or Relapsed Acute Myeloid Leukemia

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Annamycin
  • Sponsor:Moleculin Biotech Inc.

Oesophageal cancer metastatic+3

Recruiting

Study of Trastuzumab Deruxtecan and Drug Combination for Patients with Advanced or Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Daiichi Sankyo Inc.

Relapsing-remitting multiple sclerosis

Recruiting

Study on Anti-CD20 Therapy and Drug Combination for Patients with Relapsing-Remitting Multiple Sclerosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dimethyl Fumarate
  • Sponsor:Centre Hospitalier Universitaire De Montpellier

Oesophageal squamous cell carcinoma

Recruiting

Study on Tislelizumab for Elderly Patients with Advanced Esophageal Squamous Cell Carcinoma Unfit for Chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tislelizumab
  • Sponsor:University Hospital Of Clermont-Ferrand

Acute myeloid leukaemia

Recruiting

Study on Ivosidenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Non-small cell lung cancer

Recruiting

Study on MaaT033 and Cemiplimab for Patients with Advanced Non-Small Cell Lung Cancer Resistant to PD-1/PD-L1 Blockade Due to Antibiotic Use

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Institut Gustave Roussy

Hormone-dependent prostate cancer

Recruiting

Study on the Effects of Darolutamide and Drug Combination for Patients with Metastatic Hormone-Naïve Prostate Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Granulomatosis with polyangiitis

Recruiting

Study on Obinutuzumab for Patients with Relapsing Granulomatosis with Polyangiitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Plasma cell myeloma

Recruiting

Study Comparing Elranatamab and Lenalidomide with Daratumumab and Lenalidomide for Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Chambery

What the registry says about research in the country

01 Hematologic Oncology

Innovative research focusing on multiple myeloma and various lymphomas, evaluating novel therapeutic combinations and treatment strategies.

  • Multiple Myeloma Treatments
  • Follicular Lymphoma Studies
  • Diffuse Large B-cell Lymphoma Research

Advanced trials exploring combinations of immunotherapy and targeted treatments for blood cancers.

02 Lung Cancer Research

Studies examining innovative treatments for non-small cell lung cancer, particularly focusing on immunotherapy approaches.

  • Immunotherapy Combinations
  • Elderly Patient Treatment Options
  • Novel Therapeutic Strategies

Emphasis on improving treatment outcomes through targeted and combination therapies.

03 Preventive Medicine

Research on pneumococcal vaccines and preventive treatments, including studies in specialized patient populations.

  • Vaccine Immunogenicity
  • Safety Studies
  • High-Risk Patient Groups

Focus on vaccine effectiveness during acute illness conditions.

04 Breast Cancer Studies

Clinical trials examining treatments for hormone-sensitive breast cancer, including targeted therapies and hormone treatment optimization.

  • Hormone Therapy Duration
  • Metastatic Disease Management
  • Biomarker Studies

Investigation of personalized treatment approaches based on molecular markers.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.